Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F18%3A10381381" target="_blank" >RIV/00216208:11150/18:10381381 - isvavai.cz</a>
Result on the web
<a href="https://www.mdpi.com/1422-0067/19/10/3017" target="_blank" >https://www.mdpi.com/1422-0067/19/10/3017</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijms19103017" target="_blank" >10.3390/ijms19103017</a>

Result language
angličtina
Original language name
Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension
Original language description
This study investigated whether ivabradine is able to protect a hypertensive heart in the model of L-NAME-induced hypertension and to interfere with the RAAS. L-NAME administration increased systolic blood pressure and left ventricular weight, enhanced hydroxyproline concentration in the LV, and deteriorated the systolic and diastolic LV function. Ivabradine reduced HR and SBP, and improved the LV function. The serum concentrations of angiotensin Ang 1-8 (Ang II), Ang 1-5, Ang 1-7, Ang 1-10, Ang 2-8, and Ang 3-8 were decreased in the L-NAME group and ivabradine did not modify them. The serum concentration of aldosterone was enhanced by L-NAME and ivabradine reduced these changes. We conclude that the protective effect of ivabradine might have been associated with the reduction of the aldosterone level.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30105 - Physiology (including cytology)

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)